SCOR's Quiet Strength: Buffers, Deleveraging, and the Second Arbitration

A clean H1 beat and 220% solvency, yet SCOR keeps banking prudence — with a new Covéa arbitration hanging over Life & Health and a retrocession rethink teed up for December.

SCR.PA · Earnings Call · 2026-07-30

A clean beat, banked twice over

SCOR SE's second quarter was, by any measure, strong: H1 net income of EUR 409 million, an annualized ROE of 19%, a P&C combined ratio below 80%, and a solvency ratio of 220% — at the very top of the 185–220% target range. Yet the most telling moment of the call was the leadership's insistence on banking the good news rather than reporting it. Asked by Shanti Kang where the next euro of favorable cat experience would go if 2026 stays benign, Group CFO Philipp Ruede was emphatic: “directionally, we would not let the good cat go through P&L, but rather continue in our current approach, which is to use it as an opportunity to build buffers in IFRS and in spirit, normalize to an 87% cat ratio.” — Philipp Ruede, Group CFO · 2026-07-30 This property cat discipline converts a benign loss environment directly into balance sheet resilience. In Q1, SCOR transferred CHF 300 million from IFRS into best-estimate liabilities; in Q2, Thierry Leger says they added "actually more than in Q1" — continuing a buffer-building journey that began in mid-2023 but has clearly accelerated. Last October, François de Varenne had already signaled the pace: “the amount accumulated in Q1, Q2 and Q3 is of the same magnitude of what we did for the entire year 2024.” — François de Varenne, Deputy CEO and Group CFO · 2025-10-31 Now the analyst community is beginning to notice that the solvency ratio sits at the top of the optimal range, prompting Will Hardcastle to ask whether the range itself might move. Leger's answer was terse but telling: “directionally, we want to operate higher.” — Thierry Leger, Group CEO · 2026-07-30

You will note that we have added in Q1 and that we have added in Q2, again, actually more than in Q1. And so we continue on that journey.
Thierry Leger, Group CEO · 2026-07-30

The deleverage keyword spiked with this quarter's earnings — and for good reason. Beyond buffers, SCOR has been actively cutting debt leverage and extending asset duration from 4.1 to 4.4 years, done fully through cash instruments: selling short-duration corporate bonds and buying long-maturity government paper to better match Life & Health liabilities, even picking up a bit of yield in the process.

The arbitration cloud over Life & Health

The one genuine blemish in an otherwise clean print is Life & Health's insurance service result of EUR 157 million, which includes a negative EUR 64 million one-off arbitration impact. This is a distinctly new development relative to prior quarters: at the March 2026 call, management described the underlying Covéa arbitration as closed and awaiting a panel decision "mid-2026 or by the summer." Now, Covéa has filed a *second* arbitration — this time to cancel the 2021 global settlement agreement itself, and to defer the existing proceeding by two to three years. Jean-Paul Conoscente's response was measured but confident:

On the second arbitration, we are very confident. Personally, it ranks pretty low on my list of worries.
Jean-Paul Conoscente, Executive (likely underwriting or related function) · 2026-07-30

SCOR flags the EUR 64 million charge (EUR 49 million net of tax) as a subsequent event in the half-year report, with provisions unchanged at best estimate liability under both IFRS and Solvency II. This is a recurring, company-specific overhang — the best-estimate treatment doing the work of containing a legal tail that analysts clearly still worry about. But note the shift in SCOR's own narrative: from "we're waiting for a decision" (March) to "we have a new arbitration to defend, and we're confident" (July).

When growth is an outcome, not a target

The top line is softening more than peers might expect. P&C insurance revenue is being dragged by EGPI revisions (−2%) and FX (−2%), leaving constant-FX growth roughly flat. Management framed the EGPI revision as a deliberate move toward conservatism — insurance companies struggling to meet 2025 premium estimates, leading SCOR to take a more cautious view of 2026. Jean-Paul Conoscente explained this is now done every quarter, with underwriters assessing cedent estimates against the latest information. This is consistent with the long-held stance from the prior call — growth is "an outcome and not a target" (“we will give quality or underwriting priority, and therefore, growth will be an outcome and not a target.” — Thierry Leger, Group CEO · 2026-03-04) — but the Surety keyword spiking this quarter signals where the wallet is growing instead: surety in Brazil, a market that has grown substantially and profitably over two years; surety in India; and the U.S., where excess-of-loss pricing has firmed after a run of losses. Alternative solutions remain the standout: premiums up more than 70% year-to-date, and 133% at the June/July renewals. Notably, this runs counter to some peers flagging demand headwinds in the segment — SCOR sees clients using AIS as a capital management tool regardless of cycle, and its market share relative to leaders remains small. Finally, a forward-looking theme surfaced repeatedly and is worth flagging for the December Investor Day: whether SCOR will reduce its reliance on retrocession. James Shuck (Citi) pushed on whether the high gross-to-net ISR giveaway is the right model "given the strength of the balance sheet now." Thierry Leger's concession was a clear hook for the CMD: “It's also the prudence that we were able to build up that this is certainly going to be part of the reflection in the next strategic plan, whether that level of retrocession can or should be reduced.” — Thierry Leger, Group CEO · 2026-07-30 For investors, SCOR is turning an extraordinarily clean earnings print into an even stronger balance sheet — and teeing up a capital-returns question (less retro, more solvency, possibly more dividends) for December 3rd.